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Purpose: Little is known about the relationship between brain-derived neurotrophic factor (BDNF) gene polymorphisms and 
psychiatric symptoms in diabetes patients. We investigated the effects of BDNF Val/66/Met polymorphism, glucose status, psy-
chological susceptibility, and resilience on anxiety and depression symptoms in patients newly diagnosed with type 2 diabetes 
mellitus (T2DM).
Materials and Methods: We examined biochemical factors and BDNF polymorphism in 89 patients who were newly diagnosed 
with T2DM. Psychiatric symptoms were investigated with the Hospital Anxiety and Depression Scale (HADS), and the Connor-
Davidson Resilience Scale (CD-RISC) and Impact of Event Scale (IES) were used to assess psychological resilience and suscepti-
bility to psychological distress, respectively. Logistic regression analyses were conducted to investigate factors associated with 
psychiatric symptoms.
Results: We determined that 62 patients (70%) were Met-carriers. No significant differences were found between the Val/Val ho-
mozygous and Met-carrier groups regarding age, sex, body mass index, and clinical factors related to glycemic control and lipid 
profiles. HADS-anxiety and HADS-depression scores and IES factor scores were higher in the Met-carrier than the Val/Val homo-
zygous group. Hemoglobin A1c (HbA1c) level was significantly inversely correlated with the severity of depressive symptoms. Re-
silience factors showed significant inverse correlations, and IES factors showed positive correlations with depressive symptom 
severity. In the logistic regression analysis model, depressive symptoms were significantly associated with HbA1c and BDNF 
polymorphism, whereas only the hyperarousal factor of the IES scale was associated with anxiety.
Conclusion: Depressive symptoms are associated with the presence of the Met-carriers and lower HbA1c in patients newly diag-
nosed with T2DM.
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INTRODUCTION
The prevalence of depression in diabetic patients is approxi-
mately twice that observed in the general population.1 Type 2 
diabetes mellitus (T2DM) and depression are multi-factorial 
polygenic disorders influenced by both environmental and ge-
netic factors, as well as insulin resistance (IR), and their rela-
tionship has been widely investigated.2 T2DM is a chronic dis-
ease that has to be managed with lifestyle modifications and/
or medications throughout one’s life, and therefore, diabetic 
patients tend to experience diverse psychological changes, in-
cluding anxiety, depression, disappointment, and despair, once 
they are diagnosed. These psychological problems may result in 
low compliance to treatment, and emotional symptoms can ex-
acerbate T2DM-associated physiological symptoms.3,4 
Eaton, et al.5 reported that depressive disorders increase the 
prevalence of T2DM, whereas others have demonstrated that 
impaired glucose control can affect mood. Lustman, et al.6 
suggested that hyperglycemia can increase anxiety in type 1 
diabetic patients, and Testa and Simonson7 demonstrated that 
depressive symptoms in T2DM patients could be ameliorated 
by improving various metabolic factors. Other studies have 
also reported that the presence of IR aggravates depressive 
mood.2,8,9 Depression is one of the common symptoms that is 
most likely to occur within 1 year after T2DM diagnosis.10 Lust-
man, et al.11 reported that depressive disorder persisted as 
long as 5 years in T2DM and that 92% of those who had expe-
rienced severe depressive symptoms required medical treat-
ment. Taken together, available evidence suggests that there is 
an interactive relationship between T2DM and depression 
and that early diagnosis and treatment are crucial for diabetic 
patients. 
Genetic factors have been reported to be associated with 
psychological problems, including depression.12 Brain-derived 
neurotrophic factor (BDNF) is a neurotrophic factor that plays 
an important role in neurogenesis and neuroprotection. The 
BDNF gene is located at chromosome 11p14.1 and has some 
polymorphic markers: a single nucleotide polymorphism (SNP) 
at nucleotide 196 (G/A) results in the substitution of methio-
nine for valine at codon 66 (val/66/met, rs6265) of the pre-pro-
tein. This polymorphism affects BDNF intracellular processing, 
and the Met-allele is related with reduced activity-dependent 
BDNF secretion.13 The BDNF Val/66/Met polymorphism is a 
common genetic variant and is known to be associated with 
neuropsychiatric disorders, including Parkinson’s disease, Al-
zheimer's disease, depression, obsessive compulsive disorder, 
eating disorder, and memory impairment.13-18 
Krabbe, et al.19 observed a significant relationship between 
glucose metabolism and BDNF, wherein BDNF plasma con-
centrations in T2DM patients were lower than those in healthy 
controls. Moreover, BDNF was reported to have a preventive 
role in the progression to T2DM in a study of pre-diabetic mice.20 
Taken together, this evidence implies that BDNF significantly 
influences the development of depression and T2DM.19,20 
Resilience in psychology is defined as an individual’s ability 
to cope with stress and adversity.21 Resilience is a dynamic pro-
cess whereby individuals exhibit positive behavioral adaptation 
when they encounter stressful events. Stress levels in newly di-
agnosed T2DM patients may vary depending on their resil-
ience capacity. 
BDNF polymorphism has been shown to be associated with 
anxiety and depressive symptoms in neuropsychiatric pa-
tients with Parkinson’s disease, Alzheimer’s disease, obsessive 
compulsive disorder, and eating disorder.13-18 However, only a 
few studies have investigated these relationships among T2DM 
patients, and it is unclear if this relationship exists in Korean 
patients. Here, we investigated the effects of the BDNF Val/66/
Met polymorphism, glucose status, psychological resilience, 
and susceptibility to emotional distress in newly diagnosed 
Korean T2DM patients.
MATERIALS AND METHODS
Diabetic patients and clinical evaluation
Patients who were newly diagnosed with T2DM (n=100) were 
recruited at Gangnam Severance Hospital from 2010 to 2011. 
Participants were recruited into this study if they met one or 
more of the following four criteria: 1) fasting plasma glucose 
(FPG) levels ≥126 mg/dL, 2) 2-hr plasma glucose levels ≥200 
mg/dL following a 75-g oral glucose tolerance test, 3) random 
plasma glucose level ≥ 200 mg/dL with typical diabetes symp-
toms, and 4) hemoglobin A1c (HbA1c) ≥6.5%.22 Exclusion cri-
teria were having acute or serious medical illnesses, such as 
cancer, end-stage renal disease, acute myocardial infarction, 
and/or liver cirrhosis, which may affect emotional symptoms.
Among 100 subjects, 11 were excluded for the following 
reasons: three patients refused blood sampling, six provided 
unreliable answers on the questionnaire, and two had histo-
ries of psychiatric medication use. Ultimately, a total of 89 pa-
tients were included in the study. Every subject provided writ-
ten informed consent prior to participation. This study was 
approved by an Institutional Review Board of Gangnam Sever-
ance Hospital at Yonsei University (IRB number: 3-2011-0022).
Blood samples were taken after overnight fasting. Serum 
glucose levels were measured by a standard glucose oxidase 
method (747 Automatic Analyzer, Hitachi, Tokyo, Japan). Se-
rum c-peptide and insulin levels were determined by com-
mercially available assay kits (RIA Kit, Daiichi, Japan). IR was 
estimated using the Homeostasis Model Assessment of Insu-
lin Resistance (HOMA-IR) index, calculated from the follow-
ing formula: 
HOMA–IR=   fasting insulin (μU/mL)×FPG (mmol/L)/22.523
Total cholesterol (TC), high-density lipoprotein-cholesterol 
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(HDL-C), and triglycerides (TG) were measured with a chemi-
cal analyzer (Hitachi 747). Serum low-density lipoprotein-cho-
lesterol (LDL-C) levels were calculated according to the Friede-
wald formula.24 HbA1c was measured by immunoturbidimetry 
(Cobas Integra 800, Roche, Mannheim, Germany). Body mass 
index (BMI) was calculated with the following formula: weight 
(kg)/height (m)2.
Psychological assessment 
To examine the effects of psychological resilience and suscep-
tibility on depression and anxiety, psychological status of the 
subjects was measured with appropriate questionnaires, in-
cluding the Hospital Anxiety and Depression Scale (HADS), the 
Connor-Davidson Resilience Scale (CD-RISC), and the Impact 
of Event Scale (IES).21,25,26 HADS is a self-reporting questionnaire 
and consists of seven questions assessing anxiety (HADS-a) 
and seven questions assessing depression (HADS-d). It is de-
signed to screen for anxiety and depression symptoms in non-
psychiatric patients. A score of eight or higher indicates clinically 
significant emotional distress.27 Disease-related psychological 
susceptibility was measured with the IES, which measures the 
amount of distress that the subjects associate with a specific 
event or condition, in this case T2DM, for the previous 14 days. 
The questionnaire consists of 22 questions with five-point Lik-
ert scale for four factors: seven items for intrusiveness, eight 
items for avoidance, two items for sleep problems, and five 
items for hyperarousal. The CD-RISC measures the amount of 
resilience, which is defined as an individual’s ability to cope 
with stress.21 The questionnaire consists of 25 statements that 
assess five factors: self-efficacy, self-confidence, optimism, 
self-control, and spirituality/autonomy. The Korean versions of 
these questionnaires have been validated in medical prac-
tice.26-28 Internal consistency was assessed by calculating Cron-
bach’s alpha values, and the results were found to be satisfacto-
ry (HADS-a, 0.89; HADS-d, 0.86; IES, 0.93; CD-RISC, 0.93).26-28
Genetic analysis
Blood samples were collected in EDTA tubes and stored at -20°C 
until the experiments. Genomic DNA (gDNA) was extracted 
from samples using QIAamp DNA Blood Midi Kits (#51185, 
Qiagen, Valencia, CA, USA) according to the manufacturer’s di-
rections. Amplification of gDNA was carried out using TopTaqTM 
DNA Polymerase (#200205, Qiagen); the amplification condi-
tions consisted of an initial denaturation at 94°C for 5 min; fol-
lowed by 35 cycles of denaturing at 94°C for 30 sec, annealing 
at 60.5°C for 30 sec, extension at 72°C for 30 sec; and post-elon-
gation at 72°C for 10 min. Polymerase chain reaction (PCR) 
primers were designed with the following sequences of hBDNF: 
forward 5'-AAACATCCGAGGACAAGGTG-3'and reverse 
5'-CCTCATGGACATGTTTGCAG -3'. PCR products were read 
with an automated ABI Prism 3730 Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA) and were scored using Ge-
neScan, ver. 3.1 (Applied Biosystems). Met/Val BDNF poly-
morphism was determined with Reference SNP ID rs6265. 
The polymorphism distribution of the polymorphism did not 
deviate significantly from Hardy-Weinberg equilibrium (χ2(1)= 
0.51, p=0.47).29
Statistical analyses
Statistical analyses were performed with SPSS software (ver-
sion 25.0; IBM Corp., Armonk, NY, USA). Results are expressed 
as means±standard deviations or proportions. The Kolmogorov-
Smirnov test was used to test for normality. Sociodemographic 
and psychological characteristics of Val/Val homozygous and 
Met-carrier patient groups were compared using the indepen-
dent t-test and Mann-Whitney test. The chi-square test was 
used to assess categorical variables. Since all psychological as-
sessments were conducted using the scores of questionnaires, 
Spearman’s rank correlation analysis was used to assess rela-
tionships between two variables. Multivariate logistic regres-
sion analysis was employed to identify predictors of clinically 
significant depressive and anxiety symptoms. The variance 
inflation factor was calculated in consideration of multicol-
linearity, and variables with variance inflation factors of 10 or 
higher were excluded. Among the clinical characteristics, FPG, 
BMI, C-peptide, TG, TC, HDL-C, LDL-C were excluded, and 
avoidance factor was excluded among IES. For all analyses, p 
values<0.05 were considered significant.
RESULTS
As shown in Table 1, no significant differences were found be-
tween the Val/Val homozygous (Val/66/Val) and Met-carrier 







Age (yr) 49.47±10.51 48.52±10.98 0.689
Sex (M:F) 43:19 21:6 0.416
FPG (mg/dL) 163.27±49.91 174.68±65.72 0.387
HbA1c (%) 8.56±1.96 8.66±2.31 0.837
BMI 25.90±3.98 25.07±2.39 0.420
C-Pep (ng/mL) 2.16±0.86 2.50±1.30 0.179
Ins (mcIU/mL) 8.81±6.56 10.56±5.72 0.116
HOMA-IR 3.43±2.69 4.47±2.58 0.356
TC (mg/dL) 187.18±43.42 192.56±41.59 0.590
TG (mg/dL) 145.25±77.25 136.41±55.68 0.920
HDL-C (mg/dL) 44.57±9.33 41.0±10.11 0.115
LDL-C (mg/dL) 112.78±37.18 115.68±38.61 0.747
M, male; F, female; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; BMI, 
body mass index; C-pep, C-peptide; Ins, Insulin; HOMA-IR, Homeostasis Model 
Assessment of Insulin Resistance; TC, Total cholesterol; TG, Triglycerides; HDL-C, 
high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol.
Data are presented as a mean±standard deviation.
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(Val/66/Met) groups with regard to age (mean age: 49.47±10.51 
years in Met-carrier group, 48.52±10.98 years in Val/Val group), 
sex (43:19 in Met-carrier group, 21:6 in Val/Val group), BMI, lip-
id profiles, or clinical factors related to glycemic control, such as 
FPG level, HbA1c level, and HOMA-IR. However, we found sig-
nificant differences in psychological characteristics between 
groups (Table 2). Depression and anxiety symptoms represent-
ed by average HADS-a and HADS-d scores, respectively, were 
significantly higher in Met-carrier group than the Val/Val homo-
zygous group. Moreover, susceptibility represented by scores for 
all IES factors (hyperarousal, avoidance, intrusion, and sleep 
problems) were significantly higher in Met-carriers than Val/Val 
homozygotes. There were no significant differences between 
the groups for the five resilience factors (self-efficacy, self-confi-
dence, optimism, self-control, and spirituality/autonomy).
Spearman’s rank correlation analysis was performed to as-
sess associations among glucose status at the time of T2DM 
diagnosis, psychological impact caused by T2DM diagnosis, 
psychological resilience, depression, and anxiety (Table 3). 
While there was no significant correlation between glucose 
status and HADS-a, two resilience factors (self-confidence and 
self-control) were inversely correlated with HADS-a score, and 
the IES factors (hyperarousal, avoidance, intrusion, and sleep 
problems) were positively correlated with HADS-a score. 
HADS-d score was inversely correlated with serum HbA1c lev-
el and four resilience factors (self-efficacy, self-confidence, op-
timism, and self-control). HADS-d score was positively corre-
lated with all four IES factors.
The subjects were further subdivided according to the pres-
ence of clinically significant anxiety or depression symptoms 
according to HADS cutoff scores. Among the 89 patients, 23.6% 
exhibited significant anxiety, and 36% appeared to have signifi-
cant depression when evaluated by HADS-a and HADS-d, re-
spectively. Logistic regression analyses were performed for these 
subgroups to identify predictors for significant anxiety and de-
pression, and the following variables were included in the anal-
ysis as potential predictors: clinical characteristics (sex, age, 
HbA1c, HOMA-IR, and BDNF polymorphism) and psychologi-







HADS-a 5.76±3.24 4.22±2.59 0.032
HADS-d 6.73±3.44 4.78 ± 2.59 0.010
Resilience factors
Self-efficacy 23.79±8.52 23.85±6.18 0.598
Self-confidence 23.27±5.54 23.18±6.53 0.771
Optimism 15.83±2.98 15.88±4.14 0.565
Self-control 9.16±2.23 9.37±2.43 0.629
Spirituality/autonomy 5.46±1.81 5.03±2.36 0.551
IES factors
Hyperarousal 12.95±10.12 6.51±5.97 0.003
Avoidance 12.66±7.59 7.07±4.64 0.001
Intrusion 6.67±5.60 4.03±3.79 0.027
Sleep problems 6.32±4.86 2.96±3.50 0.001
HADS-a, average scores for anxiety subscales of the Hospital Anxiety and 
Depression Scale; HADS-d, average scores depression subscales of the Hos-
pital Anxiety and Depression Scale; IES, Impact of Event Scale.
Data are presented as mean±standard deviation.







Sex (ref. Male) 2.391 0.600–9.524 0.216
Age 1.072 0.993–1.156 0.076
HbA1c* 0.657 0.456–0.945 0.024
BDNF* (ref. Val/Val homozygote) 4.673   1.040–23.242 0.046
HOMA-IR 1.008 0.799–1.270 0.949
Resilience factors
Self-efficacy 0.909 0.767–1.077 0.270
Self-confidence 1.131 0.919–1.394 0.246
Optimism 0.844 0.595–1.197 0.341
Self-control 0.837 0.553–1.267 0.400
Spirituality/autonomy 0.773 0.538–1.112 0.165
IES factors
Hyperarousal 0.992 0.842–1.170 0.077
Intrusion 1.104 0.924–1.319 0.278
Sleep problems 1.164 0.876–1.547 0.295
HbA1c, hemoglobin A1c; BDNF, brain-derived neurotrophic factor polymor-
phism (Met-carrier vs. Val/Val homozygote); HOMA-IR, Homeostasis Model 
Assessment of Insulin Resistance; IES, Impact of Event Scale; ref, reference. 
The Nagelkerke R-square value was 0.56 (p<0.001). 
*p<0.05.
Table 3. Correlations among HADS Score and Glucose Status, Resilience, 
and IES Factor Scores
HADS-a HADS-d
rho p value rho p value
FPG -0.080 0.472 -0.125 0.259
HbA1c -0.179 0.097 -0.232* 0.030
Resilience factors
Self-efficacy -0.195 0.067 -0.499** <0.001
Self-confidence -0.211* 0.048 -0.458** <0.001
Optimism -0.139 0.193 -0.444** <0.001
Self-control -0.156* 0.015 -0.432** <0.001
Spirituality/autonomy 0.041 0.701 -0.176 0.099
IES factors
Hyperarousal 0.533** <0.001 0.417** <0.001
Avoidance 0.320** 0.002 0.208* 0.049
Intrusion 0.339** 0.001 0.335* 0.001
Sleep problems 0.457** <0.001 0.437** <0.001
FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; IES, Impact of Event 
Scale; HADS-a, anxiety subscale of the Hospital Anxiety and Depression Scale; 
HADS-d, depression subscale of the Hospital Anxiety and Depression Scale. 
*p<0.05, **p<0.001.
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cal characteristics (five resilience factors and three psycholog-
ical susceptibility factors). These analyses revealed that HbA1c 
level (β=0.657, p=0.024) and BDNF polymorphism (β=4.673, 
p=0.046) were associated with depression (Table 4). The only 
variable associated with anxiety in the final regression model 
was the hyperarousal factor of the IES scale (β=1.180, p=0.044) 
(Table 5).
DISCUSSION
Our findings demonstrated that depression and anxiety symp-
toms in patients newly diagnosed with T2DM are related to 
the presence of the SNP at nucleotide 196 in the BDNF gene. 
Subjects with a valine for methionine substitution (Val/66/
Met) showed significantly higher scores for both depression 
and anxiety symptoms, compared to those carrying Val/66/Val. 
There are some inconsistent results regarding the role of the 
Met allele in the development of various psychiatric symp-
toms. Some studies have reported that the Met allele is protec-
tive against psychiatric disorders, including depression, while 
others have suggested that Met-carriers face an increased risk 
for anxiety and depression.17,30-32 Similar results have indicated 
that the Met substitution for Val is a risk factor for psychiatric 
symptoms in Korean populations.33,34 Our findings suggest that 
the presence of the Met allele in patients with T2DM seems to 
be a risk factor for depression and anxiety symptoms.
We compared IES and CD-RISC scores and glucose status 
among Korean patients with T2DM divided into Met-carriers 
and Val/Val homozygotes. Met-carriers were more susceptible 
than Val/Val homozygotes when evaluated by IES factors (hy-
perarousal, avoidance, intrusion, and sleep problems). These 
results suggest that the Met-carrier group was more suscepti-
ble to psychological distress at the diagnosis of T2DM than 
the Val/Val homozygous group. However, there was no signifi-
cant difference between these two groups with regard to the 
five factors of resilience, indicating that resilience capacity may 
not be significantly associated with BDNF polymorphism. Col-
lectively, these findings suggest that BDNF polymorphism is 
associated with emotional distress and psychological suscep-
tibility but not with resilience in patients with T2DM. 
In this study, a logistic regression model including sex, age, 
HbA1c, BDNF polymorphism, HOMA-IR, resilience factors, 
and susceptibility factors revealed that depression was signifi-
cantly associated with low HbA1c and the BDNF Met allele. 
There have been inconsistent reports regarding the relation-
ship between parameters of glycemic control and depression 
in diabetic patients. One study reported that depressive symp-
toms are inversely correlated with the parameters of glycemic 
control, while others found no correlation between the two vari-
ables.6,35,36 However, the mean durations of T2DM in those stud-
ies varied from 5 to 10 years. Unlike previous studies, we ex-
amined the relationship between depressive symptoms and 
glycemic control at the time of T2DM diagnosis.
Interestingly, we found that HbA1c levels were lower in 
subjects with depressive symptoms. Considering that HbA1c 
represents the average glucose values for the previous 2–3 
months, it suggests that patients with depressive symptoms had 
better glucose control. Patients with more depressive symptoms 
tend to be concerned about their health and to visit the hospi-
tal more frequently with mild illnesses than those without de-
pressive symptoms.37 That people with depressive symptoms 
may react more sensitively to changes in their health condi-
tions related to high glucose level and may visit their physi-
cians more frequently may explain the lower HbA1c levels in 
depressed subjects in the present study. In other words, the in-
terval between T2DM onset and the time to diagnosis may be 
shorter in patients with depressive symptoms even though we 
did not exactly assess hospital visit frequency in this study. In 
another study that conducted 2 years of follow-up after being 
newly diagnosed with T2DM, depressive symptoms and an in-
crease in HbA1c were not related after 1 year, but were associ-
ated after 2 years. Similar findings have been reported in other 
studies, suggesting that the longer the patient suffers from dia-
betes, the more diabetes distress, which is characterized as 
burdens, worries, and fears specific to people living with diabe-
tes, will be associated with an increase in HbA1c.38 Therefore, in 
order to accurately understand the association between HbA1c 
and depressive symptoms, a long-term study over time from 
the point of diagnosis of diabetes may be meaningful.
Spearman’s rank correlation analyses revealed significant 







Sex (ref. Male) 2.064 0.492–8.665 0.322
Age 1.069 0.997–1.147 0.062
HbA1c 0.696 0.462–1.046 0.081
BDNF (ref. Val/Val homozygote) 0.600 0.137–2.623 0.498
HOMA-IR 1.058 0.815–1.373 0.671
Resilience factors
Self-efficacy 0.951 0.781–1.157 0.613
Self-confidence 1.097 0.865–1.390 0.445
Optimism 0.989 0.652–1.500 0.958
Self-control 0.976 0.627–1.519 0.913
Spirituality/autonomy 0.858 0.610–1.206 0.377
IES factors
Hyperarousal* 1.180 1.001–1.140 0.044
Intrusion 0.933 0.786–1.107 0.426
Sleep problem 0.987 0.738–1.320 0.931
HbA1c, hemoglobin A1c; BDNF, brain-derived neurotrophic factor (Met-carrier 
vs. Val/Val homozygote); HOMA-IR, Homeostasis Model Assessment of Insu-
lin Resistance; IES, Impact of Event Scale; ref, reference. 
The Nagelkerke R-square value was 0.41 (p<0.001). 
*p<0.05.
364
BDNF Polymorphism and Depression in Diabetes
https://doi.org/10.3349/ymj.2021.62.4.359
negative correlations between depressive symptoms and resil-
ience scores and significant positive correlations between de-
pressive symptoms and psychological susceptibility. This im-
plies that the susceptibility factor is more important than the 
protective factor to experience depressive symptoms when 
patients are newly diagnosed with T2DM.
HADS has been used to assess emotional symptoms in DM 
patients in previous studies.1,6 According to HADS-d score, we 
found that 32 newly diagnosed subjects (36%) appeared to have 
significant depressive symptoms, and 9 subjects (10%) exhibited 
severe depressive symptoms. 21 subjects (23.6%) were found to 
have significant anxiety symptoms, and 7 subjects (7.8%) were 
found to have severe anxiety symptoms according to HADS-a 
score. These observations are consistent with previous studies 
that demonstrated higher prevalence of depression and anxiety 
in diabetic patients, compared to the general population.1,39-41 
This study provides novel clinical evidence that patients who 
are newly diagnosed with T2DM show an increased preva-
lence of depression and anxiety. Adriaanse, et al. reported that 
pre-diabetic and diabetic females suffered from more depres-
sive symptoms than the general population.42 They suggested 
that the prevalence of depressive symptoms might be higher 
even in pre-diabetes status. However, 72% of the subjects in this 
study were male, which made it difficult to address the role of 
sex. In general, depression is more prevalent in females. In this 
regard, the presence of depressive symptoms in patients newly 
diagnosed with T2DM may be higher in general than this sam-
ple, which needs further investigation.
There are some limitations to this study. First, the sample 
size was relatively small; however, the genetic distribution of 
the sample was not significantly deviated from Hardy-Wein-
berg equilibrium. Second, this study did not include a control 
group, and thus, we could not directly compare the prevalence 
of depression and anxiety in patients newly diagnosed with 
T2DM with those in non-diabetic individuals according to 
BDNF polymorphism. Third, the subjects were not fully evalu-
ated with structured diagnostic interviews or comprehensive 
psychological tests. Lastly, the male proportion over 2/3 may 
contribute to equivocal findings about correlation between glu-
cose control (HbA1c) and depressive symptoms in this study. 
Further large scale study about this issue should be followed. 
Despite these limitations, the present study is the first to 
evaluate relationships between BDNF polymorphism and 
emotional symptoms in Korean patients who were newly diag-
nosed with T2DM. A larger study is necessary to replicate or 
confirm these preliminary findings.
In conclusion, our study demonstrated that the BDNF Val/66/
Met polymorphism is associated with depressive symptoms in 
patients newly diagnosed with T2DM. This study also showed 
that depressive patients tended to show better HbA1c levels 
when they were newly diagnosed, although this may be due 
to the tendency of depressive patients to frequently seek medi-
cal assistance. Additionally, we confirmed that emotional symp-
toms are associated with psychological characteristics, includ-
ing resilience and susceptibility to stressful life events. 
One study reported that half of diabetic patients suffer from 
depression; however, only half of clinically depressed diabetic 
patients are treated for their psychological symptoms.43 Our 
findings suggest that when treating patients with diabetes, a 
biopsychosocial approach to evaluate depression, as well as 
good glycemic control, may improve treatment outcomes. Phy-
sicians and psychiatrists should cooperate to improve early de-
pression diagnosis and facilitate active treatment to improve pa-
tient quality of life.
ACKNOWLEDGEMENTS
This project was funded by Sanofi-Aventis. 
AUTHOR CONTRIBUTIONS
Conceptualization: Jin Sun Ryu, Young Mi Lee, Ji Sun Nam, and Jeong-
Ho Seok. Data curation: Young Mi Lee and Ji Sun Nam. Formal analy-
sis: Jin Sun Ryu and Young Mi Lee. Funding acquisition: Ji Sun Nam. 
Investigation: Jin Sun Ryu and Young Mi Lee. Methodology: Shinae 
Kang, Ji Sun Nam, and Jeong-Ho Seok. Project administration: Young 
Mi Lee. Resources: Yu-Sik Kim, Jong Suk Park, and Ji Sun Nam. Soft-
ware: Jin Sun Ryu and Young Mi Lee. Supervision: Chul Woo Ahn, Ji 
Sun Nam, and Jeong-Ho Seok. Validation: all authors. Visualization: 
Jin Sun Ryu and Young Mi Lee. Writing—original draft: Young Mi Lee. 
Writing—review & editing: Jin Sun Ryu. Approval of final manuscript: 
all authors.
ORCID iDs
Jin Sun Ryu https://orcid.org/0000-0001-7268-3822
Young Mi Lee https://orcid.org/0000-0002-2212-6689
Yu-Sik Kim  https://orcid.org/0000-0002-2921-6433
Shinae Kang  https://orcid.org/0000-0002-9719-4774
Jong Suk Park  https://orcid.org/0000-0002-5385-1373
Chul Woo Ahn https://orcid.org/0000-0003-3733-7486
Ji Sun Nam https://orcid.org/0000-0001-8655-5258
Jeong-Ho Seok https://orcid.org/0000-0002-9402-7591
REFERENCES
1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The preva-
lence of comorbid depression in adults with diabetes: a meta-
analysis. Diabetes Care 2001;24:1069-78.
2. Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D, et al. 
Insulin resistance in patients with depression and its changes dur-
ing the clinical course of depression: minimal model analysis. 
Metabolism 2000;49:1255-60.
3. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, 
Clouse RE. Depression and poor glycemic control: a meta-analyt-
ic review of the literature. Diabetes Care 2000;23:934-42.
4. Rubin RR, Peyrot M. Psychosocial problems and interventions in 
diabetes. A review of the literature. Diabetes Care 1992;15:1640-57.
5. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and 
risk for onset of type II diabetes. A prospective population-based 
study. Diabetes Care 1996;19:1097-102.
365
Jin Sun Ryu, et al.
https://doi.org/10.3349/ymj.2021.62.4.359
6. Lustman P, Carney R, Amado H. Acute stress and metabolism in 
diabetes. Diabetes Care 1981;4:658-9.
7. Testa MA, Simonson DC. Health economic benefits and quality of 
life during improved glycemic control in patients with type 2 dia-
betes mellitus: a randomized, controlled, double-blind trial. JAMA 
1998;280:1490-6.
8. Winokur A, Maislin G, Phillips JL, Amsterdam JD. Insulin resistance 
after oral glucose tolerance testing in patients with major depres-
sion. Am J Psychiatry 1988;145:325-30.
9. Tashiro A, Hongo M, Ota R, Utsumi A, Imai T. Hyper-insulin re-
sponse in a patient with depression. Changes in insulin resistance 
during recovery from depression. Diabetes Care 1997;20:1924-5.
10. Kovacs M, Obrosky DS, Goldston D, Drash A. Major depressive 
disorder in youths with IDDM. A controlled prospective study of 
course and outcome. Diabetes Care 1997;20:45-51.
11. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin 
EH, et al. Effects of nortriptyline on depression and glycemic con-
trol in diabetes: results of a double-blind, placebo-controlled trial. 
Psychosom Med 1997;59:241-50.
12. Levinson DF. The genetics of depression: a review. Biol Psychiatry 
2006;60:84-92.
13. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Ber-
tolino A, et al. The BDNF val66met polymorphism affects activity-
dependent secretion of BDNF and human memory and hippocam-
pal function. Cell 2003;112:257-69.
14. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, 
Kanazawa I, et al. Association studies of multiple candidate genes 
for Parkinson’s disease using single nucleotide polymorphisms. 
Ann Neurol 2002;51:133-6.
15. Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, 
Riva MA, et al. Association between the BDNF 196 A/G polymor-
phism and sporadic Alzheimer’s disease. Mol Psychiatry 2002;7: 
136-7.
16. Sen S, Nesse RM, Stoltenberg SF, Li S, Gleiberman L, Chakravarti 
A, et al. A BDNF coding variant is associated with the NEO person-
ality inventory domain neuroticism, a risk factor for depression. 
Neuropsychopharmacology 2003;28:397-401.
17. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. Se-
quence variants of the brain-derived neurotrophic factor (BDNF) 
gene are strongly associated with obsessive-compulsive disorder. 
Am J Hum Genet 2003;73:370-6.
18. Ribasés M, Gratacòs M, Armengol L, de Cid R, Badía A, Jiménez L, 
et al. Met66 in the brain-derived neurotrophic factor (BDNF) pre-
cursor is associated with anorexia nervosa restrictive type. Mol 
Psychiatry 2003;8:745-51.
19. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmus-
sen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) 
and type 2 diabetes. Diabetologia 2007;50:431-8.
20. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. 
Decreased serum brain-derived neurotrophic factor levels in ma-
jor depressed patients. Psychiatry Res 2002;109:143-8.
21. Connor KM, Davidson JR. Development of a new resilience scale: 
the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxi-
ety 2003;18:76-82.
22. American Diabetes Association. Standards of medical care in dia-
betes--2010. Diabetes Care 2010;33 Suppl 1:S11-61.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, 
Turner RC. Homeostasis model assessment: insulin resistance and 
β-cell function from fasting plasma glucose and insulin concentra-
tions in man. Diabetologia 1985;28:412-9.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the con-
centration of low-density lipoprotein cholesterol in plasma, with-
out use of the preparative ultracentrifuge. Clin Chem 1972;18:499-
502.
25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983;67:361-70.
26. Lim HK, Woo JM, Kim TS, Kim TH, Choi KS, Chung SK, et al. Reli-
ability and validity of the Korean version of the Impact of Event 
Scale-Revised. Compr Psychiatry 2009;50:385-90.
27. Oh SM, Min KJ, Park DB. A study on the standardization of the 
hospital anxiety and depression scale for Koreans: a comparison 
of normal, depressed and anxious groups. J Korean Neuropsychi-
atr Assoc 1999;38:289-96. 
28. Baek HS, Lee KU, Joo EJ, Lee MY, Choi KS. Reliability and validity 
of the Korean version of the connor-davidson resilience scale. Psy-
chiatry Investig 2010;7:109-15.
29. Hardy GH. Mendelian proportions in a mixed population. Science 
1908;28:49-50.
30. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G, et al. 
Family-based association study of 76 candidate genes in bipolar 
disorder: BDNF is a potential risk locus. Brain-derived neutrophic 
factor. Mol Psychiatry 2002;7:579-93.
31. Geller B, Badner JA, Tillman R, Christian SL, Bolhofner K, Cook 
EH Jr. Linkage disequilibrium of the brain-derived neurotrophic 
factor Val66Met polymorphism in children with a prepubertal and 
early adolescent bipolar disorder phenotype. Am J Psychiatry 2004; 
161:1698-700.
32. Groves JO. Is it time to reassess the BDNF hypothesis of depres-
sion? Mol Psychiatry 2007;12:1079-88.
33. Kim JM, Kim SW, Stewart R, Kim SY, Shin IS, Park MH, et al. Sero-
tonergic and BDNF genes associated with depression 1 week and 1 
year after mastectomy for breast cancer. Psychosom Med 2012;74: 
8-15.
34. Kim JM, Stewart R, Bae KY, Kim SW, Kang HJ, Shin IS, et al. Seroto-
nergic and BDNF genes and risk of depression after stroke. J Affect 
Disord 2012;136:833-40.
35. Surridge DH, Erdahl DL, Lawson JS, Donald MW, Monga TN, Bird 
CE, et al. Psychiatric aspects of diabetes mellitus. Br J Psychiatry 
1984;145:269-76.
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